A large insurance-claims study found that patients with a formal cannabis use disorder diagnosis had roughly 2.6 times the rate of medical complications within 90 days of wrist fracture surgery compared with matched controls. While the association is notable and consistent across several complication types, the study design cannot prove that cannabis caused the higher complication rates, and unmeasured factors may explain much of the difference.

Distal radius fractures are among the most common fractures treated surgically, and the proportion of surgical patients carrying a cannabis use disorder diagnosis has doubled over the past decade. Surgeons and primary care physicians increasingly encounter patients who use cannabis and need guidance on perioperative risk, yet high-quality outcome data specific to this population are scarce. Without reliable evidence, clinicians are left making assumptions in either direction, potentially undertreating risk or unnecessarily alarming patients. This study offers the largest matched comparison to date, making its findings directly relevant to preoperative conversations even as its limitations demand careful interpretation.

Open reduction and internal fixation of distal radius fractures is a bread-and-butter orthopedic procedure with generally favorable outcomes, but little is known about how a concurrent cannabis use disorder diagnosis affects the postoperative course. The endocannabinoid system has documented interactions with immune function, vascular tone, and pain modulation, providing biological plausibility for altered surgical recovery. This study leveraged the PearlDiver Mariner database, which contains claims for over 150 million privately insured Americans, to identify 2,297 patients aged 20 to 69 with a CUD diagnosis on the day of surgery and match them 1:5 against 11,108 controls on age, sex, area deprivation index, and eight major comorbidities including tobacco use, opioid dependence, and alcohol abuse.

At 90 days, CUD patients had a 15.24% overall medical complication rate compared with 5.76% among controls. After multivariable logistic regression, significantly elevated odds were observed for pneumonia, cerebrovascular accident, pulmonary embolism, respiratory failure, and surgical site infection, all meeting the study’s conservative P less than .005 threshold. Emergency department visits (2.53% vs 1.14%) and hospital readmissions (5.79% vs 4.29%) were also higher in the CUD group. However, the absolute risk differences for several individual complications were small, and the reliance on ICD billing codes rather than clinical documentation of active cannabis use means that misclassification and residual confounding remain substantial concerns. The authors appropriately characterize their findings as hypothesis-generating and call for prospective studies that capture dose, frequency, and route of cannabis use alongside detailed surgical and fracture data.

This study asks the right question at the right time. As cannabis legalization accelerates, surgeons need outcome data to inform preoperative discussions, and this is one of the first large-scale comparisons specifically for wrist fracture surgery. The matching strategy is commendable, particularly the inclusion of tobacco and opioid use in the matching variables, which partially addresses the “sick population” concern. But the gap between a CUD billing code and actual cannabis exposure is enormous. A patient coded for CUD might have been abstinent for months, while a daily user without a formal diagnosis would appear in the control group. That asymmetry can distort results in ways no statistical adjustment fully corrects.

In my practice, I treat the preoperative period as an opportunity to have an honest, non-judgmental conversation about all substance use, including cannabis. I want to know route, frequency, and timing relative to surgery. For patients who smoke cannabis, I recommend cessation or at minimum a switch to non-inhaled forms in the weeks before and after any procedure, primarily to protect pulmonary function. I do not use claims-based associations like these to tell patients they face dramatically higher surgical risk from cannabis alone, because the data simply do not support that level of certainty.

This study sits early in the research arc for cannabis and orthopedic surgical outcomes. Prior work has examined cannabis use in the context of total joint arthroplasty and spine surgery using similar claims databases, with broadly consistent findings of elevated complication signals. However, none of these studies have been able to distinguish between the effects of cannabis itself and the constellation of behavioral and social factors that cluster with a formal CUD diagnosis. Clinicians should treat this evidence as a flag for vigilance, not as grounds for withholding surgery or overhauling informed consent language. The doubling of CUD coding prevalence over the study period also warrants attention: it likely reflects evolving documentation practices as much as rising use, which makes trend interpretations inherently unreliable.

From a pharmacological standpoint, cannabis has established interactions with anesthetic agents, can affect airway reactivity in smoked forms, and may alter pain perception in ways that complicate postoperative analgesic titration. Patients who use cannabis regularly may have altered opioid requirements, and anesthesiologists benefit from knowing this before the procedure. The elevated pneumonia and respiratory failure signals in this study are biologically plausible in heavy smokers of

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care